|
| Friday, 22 March 2019, 10:23 HKT/SGT | |
| |  | |
Source: Eisai | |
|
|
|
TOKYO, Mar 22, 2019 - (JCN Newswire) - Eisai Co., Ltd. announced that a total of seven presentations highlighting the latest data on its Alzheimer's disease/dementia pipeline, including anti-amyloid beta (Abeta) protofibril antibody BAN2401 and oral beta amyloid cleaving enzyme (BACE) inhibitor elenbecestat will be given at the 14th International Conference on Alzheimer's & Parkinson's Diseases (AD/PD) from March 26 to 31 in Lisbon, Portugal. BAN2401 and elenbecestat are being jointly developed by Eisai and Biogen Inc.
Five of the presentations will be given for BAN2401 and elenbecestat. The presentations include the study design for the Open Label Extension (OLE) portion of the BAN2401 Phase II clinical study in patients with mild cognitive impairment (MCI) due to Alzheimer's disease or mild Alzheimer's disease (collectively known as early Alzheimer?s disease) with confirmed amyloid pathology in the brain.
There will be a presentation of electrocardiogram (ECG) data to inform dose selection for E2027, a phosphodiesterase-9 (PDE9) inhibitor, discovered and developed solely by Eisai, in a Phase II study for dementia with Lewy bodies.
Eisai is aiming to realize prevention and cure of dementia through a holistic approach to dementia drug discovery research based on a foundation of over 30 years of experience of drug discovery activities in the area of Alzheimer's disease/dementia. Eisai is striving to create innovative medicines as soon as possible in order to further contribute to addressing the unmet medical needs of, as well as increasing the benefits provided to, patients and their families.
Contact:
Public Relations Department,
Eisai Co., Ltd.
+81-3-3817-5120
Topic: Press release summary
Source: Eisai
Sectors: BioTech
http://www.acnnewswire.com
From the Asia Corporate News Network
Copyright © 2025 ACN Newswire. All rights reserved. A division of Asia Corporate News Network.
|
|
|
|
